GlyProVac
Odense
About GlyProVac
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $467.0K
- Last round: Grant (Feb 2024)
- Website: glyprovac.com
- Phone: [email protected]
Industries & Categories
Biopharma
Social Profiles
Canonical: https://fsome.com/organization/glyprovac-146794 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.